Maxcyte (MXCT) Income from Continuing Operations (2020 - 2026)

Maxcyte (MXCT) has reported Income from Continuing Operations for 7 consecutive years, with -$8.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Continuing Operations rose 28.19% year-over-year to -$8.9 million in Q2 2026; TTM through Jun 2026 was -$35.6 million, a 20.41% increase from a year earlier, with the FY2025 full-year figure at -$35.3 million, down 8.58% from the prior year.
• Income from Continuing Operations was -$8.9 million for Q2 2026 at Maxcyte, down from -$4.8 million in the prior quarter.
• Over five years, Income from Continuing Operations peaked at -$4.1 million in Q1 2022 and troughed at -$12.4 million in Q3 2025.
• A 5-year average of -$8.9 million and a median of -$9.6 million in 2024 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations sank 167.55% in 2023 and jumped 53.71% in 2026, its largest moves.
• Over 5 years, Income from Continuing Operations stood at -$4.8 million in 2022, then slipped by 9.74% to -$5.3 million in 2023, then slumped by 100.78% to -$10.6 million in 2024, then grew by 9.45% to -$9.6 million in 2025, then rose by 7.52% to -$8.9 million in 2026.
• The last three Income from Continuing Operations figures came in at -$8.9 million (Q2 2026), -$4.8 million (Q1 2026), and -$9.6 million (Q4 2025), per Business Quant data.